Marwan Fakih, M.D. / Professor
Marwan Fakih, MD
Professor, Department of Medical Oncology and Therapeutics Research
Judy and Bernard Briskin Distinguished Directorship in Clinical Research
Associate Director for Clinical Services
Medical Director, Briskin Center for Clinical Research
Co-Director, Gastrointestinal Cancer Program
Section Head, GI Medical Oncology
Dr. Fakih received his medical degree from the American University of Beirut, Lebanon, in 1992. He subsequently completed a residency in Internal Medicine at the Detroit Medical Center/ Wayne State University (1992-95) and a fellowship in Hematology and Oncology at University of Pittsburgh (1998-2001).
Dr. Fakih served as an Assistant Professor at University of Pittsburgh (2001-2) before joining Roswell Park Cancer Institute (2002-2011). At Roswell Park, he was promoted to Associate Professor and served as Section Head for Gastrointestinal Cancer Section. In 2011, he joined University of Michigan as Professor of Medicine and Co-Director of the Gastrointestinal Program.
Dr. Fakih joined City of Hope in 2012 where he serves as head of the Gastrointestinal Cancers Division in the Department of Medical Oncology, co-Director of the GI Program, Medical Director of the Briskin Center for Clinical Research, and the Associate Director for Clinical Sciences.
Dr. Fakih’s research focuses on developmental therapeutics, especially in what pertains to the management of colorectal cancer. Over the last 20 years, he has conducted more than 20 investigator-initiated clinical trials and published more than 200 peer reviewed manuscripts. His research has focused on targeted therapies against EGFR, HER-2, KRAS and BRAF mutations. In addition, his research has identified predictive biomarkers of response to immunotherapy both in MSS and MSI-H colorectal cancers.
Dr. Fakih is a member of the NCI Colorectal Cancer Task Force, NRG Colorectal Cancer core committee, ACCRU Gastrointestinal Cancer core committee, and serves as the Co-Chair of the SWOG Colorectal Cancer Subcommittee.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaDate added:07/12/2023Date updated:07/12/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BayerDate added:07/12/2023Date updated:07/12/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Bristol Myers SquibbDate added:07/12/2023Date updated:07/12/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Incyte CorporationDate added:07/12/2023Date updated:07/12/2023Relationship end date:01/20/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Mirati TherapeuticsDate added:07/12/2023Date updated:07/12/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NouscomDate added:07/12/2023Date updated:07/12/2023Relationship end date:05/04/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Roche/GenentechDate added:07/12/2023Date updated:07/12/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Taiho OncologyDate added:07/12/2023Date updated:07/12/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AgenusBioDate added:07/12/2023Date updated:07/12/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:GenentechDate added:07/12/2023Date updated:07/12/2023